The status of compounded semaglutide and tirzepatide changed a lot after the FDA shortages ended. As of 2026, routine large-scale compounding of copies is generally no longer permitted, with only narrow patient-specific exceptions. This is a fast-moving legal area — here is a neutral, dated summary. It is informational only, not legal or medical advice, and we never recommend a source or vendor.
The FDA shortages ended for tirzepatide (December 2024) and semaglutide (February 2025). Once a drug is no longer in shortage, the legal basis that let compounders make copies during the shortage largely goes away (after set grace periods, which have passed). So broad compounding of semaglutide/tirzepatide copies is generally not permitted now; compounding is limited to narrow, patient-specific circumstances.
The FDA has continued to act on compounded and gray-market GLP-1s — warning about unapproved salt forms and safety, taking enforcement steps, and moving to limit these drugs on the 503B bulks list. Because this keeps evolving, treat any status as a snapshot and confirm the current picture with a licensed pharmacy or clinician.
Not a blanket ban, but once the shortage ended (Feb 2025) the basis for broad compounding of copies largely went away. Compounding is now limited to narrow, patient-specific needs. Confirm the current status with a licensed pharmacy.
503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities make larger batches under stricter FDA oversight. Both are limited when a commercial product is available and not in shortage.
Its shortage ended in December 2024, so the same limits apply. Availability is narrow and evolving; check with a licensed pharmacy or clinician.
Federal law allows expanded compounding mainly to fill shortages. When a drug leaves the shortage list, that expanded allowance ends after grace periods.
We don’t recommend sources. Talk to a clinician about an FDA-approved product from a licensed pharmacy; avoid gray-market or "research" suppliers.